Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit for a wide range of cancer types. Because only a subset of patients experience clinical benefit, there is a strong need for biomarkers that are easily accessible across diverse practice settings. Here, in a retrospec...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Nat Commun
Prif Awduron: Valero, Cristina, Lee, Mark, Hoen, Douglas, Weiss, Kate, Kelly, Daniel W., Adusumilli, Prasad S., Paik, Paul K., Plitas, George, Ladanyi, Marc, Postow, Michael A., Ariyan, Charlotte E., Shoushtari, Alexander N., Balachandran, Vinod P., Hakimi, A. Ari, Crago, Aimee M., Long Roche, Kara C., Smith, J. Joshua, Ganly, Ian, Wong, Richard J., Patel, Snehal G., Shah, Jatin P., Lee, Nancy Y., Riaz, Nadeem, Wang, Jingming, Zehir, Ahmet, Berger, Michael F., Chan, Timothy A., Seshan, Venkatraman E., Morris, Luc G. T.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7851155/
https://ncbi.nlm.nih.gov/pubmed/33526794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-20935-9
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg